199 related articles for article (PubMed ID: 25468570)
1. Genetic inactivation of TRAF3 in canine and human B-cell lymphoma.
Bushell KR; Kim Y; Chan FC; Ben-Neriah S; Jenks A; Alcaide M; Fornika D; Grande BM; Arthur S; Gascoyne RD; Steidl C; Morin RD
Blood; 2015 Feb; 125(6):999-1005. PubMed ID: 25468570
[TBL] [Abstract][Full Text] [Related]
2. TRAF3 loss-of-function reveals the noncanonical NF-κB pathway as a therapeutic target in diffuse large B cell lymphoma.
Li MY; Chong LC; Duns G; Lytle A; Woolcock B; Jiang A; Telenius A; Ben-Neriah S; Nawaz W; Slack GW; Elisia I; Viganò E; Aoki T; Healy S; Krystal G; Venturutti L; Scott DW; Steidl C
Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2320421121. PubMed ID: 38662551
[TBL] [Abstract][Full Text] [Related]
3. The prevalence and characterisation of TRAF3 and POT1 mutations in canine B-cell lymphoma.
Smith PAD; Waugh EM; Crichton C; Jarrett RF; Morris JS
Vet J; 2020 Dec; 266():105575. PubMed ID: 33323169
[TBL] [Abstract][Full Text] [Related]
4. N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma.
Edwards SK; Moore CR; Liu Y; Grewal S; Covey LR; Xie P
BMC Cancer; 2013 Oct; 13():481. PubMed ID: 24131623
[TBL] [Abstract][Full Text] [Related]
5. An oncogenic role for alternative NF-κB signaling in DLBCL revealed upon deregulated BCL6 expression.
Zhang B; Calado DP; Wang Z; Fröhler S; Köchert K; Qian Y; Koralov SB; Schmidt-Supprian M; Sasaki Y; Unitt C; Rodig S; Chen W; Dalla-Favera R; Alt FW; Pasqualucci L; Rajewsky K
Cell Rep; 2015 May; 11(5):715-26. PubMed ID: 25921526
[TBL] [Abstract][Full Text] [Related]
6. Dysregulated TRAF3 and BCL2 Expression Promotes Multiple Classes of Mature Non-hodgkin B Cell Lymphoma in Mice.
Perez-Chacon G; Adrados M; Vallejo-Cremades MT; Lefebvre S; Reed JC; Zapata JM
Front Immunol; 2018; 9():3114. PubMed ID: 30687320
[TBL] [Abstract][Full Text] [Related]
7. Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background.
Elvers I; Turner-Maier J; Swofford R; Koltookian M; Johnson J; Stewart C; Zhang CZ; Schumacher SE; Beroukhim R; Rosenberg M; Thomas R; Mauceli E; Getz G; Palma FD; Modiano JF; Breen M; Lindblad-Toh K; Alföldi J
Genome Res; 2015 Nov; 25(11):1634-45. PubMed ID: 26377837
[TBL] [Abstract][Full Text] [Related]
8. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.
Compagno M; Lim WK; Grunn A; Nandula SV; Brahmachary M; Shen Q; Bertoni F; Ponzoni M; Scandurra M; Califano A; Bhagat G; Chadburn A; Dalla-Favera R; Pasqualucci L
Nature; 2009 Jun; 459(7247):717-21. PubMed ID: 19412164
[TBL] [Abstract][Full Text] [Related]
9. Aggressive Lymphoplasmacytic Neoplasm With an Unusual In-frame Deletion of
Yan M; Meyerson H; Oduro KA; Shetty S; Yoest J
Int J Surg Pathol; 2024 Feb; 32(1):5-10. PubMed ID: 37093763
[TBL] [Abstract][Full Text] [Related]
10. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively.
Tracey L; Pérez-Rosado A; Artiga MJ; Camacho FI; Rodríguez A; Martínez N; Ruiz-Ballesteros E; Mollejo M; Martinez B; Cuadros M; Garcia JF; Lawler M; Piris MA
J Pathol; 2005 Jun; 206(2):123-34. PubMed ID: 15880597
[TBL] [Abstract][Full Text] [Related]
11. TRAF2/3 deficient B cells resist DNA damage-induced apoptosis via NF-κB2/XIAP/cIAP2 axis and IAP antagonist sensitizes mutant lymphomas to chemotherapeutic drugs.
Vashisht M; Ge H; John J; McKelvey HA; Chen J; Chen Z; Wang JH
Cell Death Dis; 2023 Sep; 14(9):599. PubMed ID: 37679334
[TBL] [Abstract][Full Text] [Related]
12. Comparative gene expression profiling identifies common molecular signatures of NF-κB activation in canine and human diffuse large B cell lymphoma (DLBCL).
Mudaliar MA; Haggart RD; Miele G; Sellar G; Tan KA; Goodlad JR; Milne E; Vail DM; Kurzman I; Crowther D; Argyle DJ
PLoS One; 2013; 8(9):e72591. PubMed ID: 24023754
[TBL] [Abstract][Full Text] [Related]
13. Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma.
Otto C; Giefing M; Massow A; Vater I; Gesk S; Schlesner M; Richter J; Klapper W; Hansmann ML; Siebert R; Küppers R
Br J Haematol; 2012 Jun; 157(6):702-8. PubMed ID: 22469134
[TBL] [Abstract][Full Text] [Related]
14. Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in mice.
Moore CR; Liu Y; Shao C; Covey LR; Morse HC; Xie P
Leukemia; 2012 May; 26(5):1122-7. PubMed ID: 22033491
[No Abstract] [Full Text] [Related]
15. Rescue of TRAF3-null mice by p100 NF-kappa B deficiency.
He JQ; Zarnegar B; Oganesyan G; Saha SK; Yamazaki S; Doyle SE; Dempsey PW; Cheng G
J Exp Med; 2006 Oct; 203(11):2413-8. PubMed ID: 17015635
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma.
Arthur SE; Jiang A; Grande BM; Alcaide M; Cojocaru R; Rushton CK; Mottok A; Hilton LK; Lat PK; Zhao EY; Culibrk L; Ennishi D; Jessa S; Chong L; Thomas N; Pararajalingam P; Meissner B; Boyle M; Davidson J; Bushell KR; Lai D; Farinha P; Slack GW; Morin GB; Shah S; Sen D; Jones SJM; Mungall AJ; Gascoyne RD; Audas TE; Unrau P; Marra MA; Connors JM; Steidl C; Scott DW; Morin RD
Nat Commun; 2018 Oct; 9(1):4001. PubMed ID: 30275490
[TBL] [Abstract][Full Text] [Related]
17. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
Davis RE; Brown KD; Siebenlist U; Staudt LM
J Exp Med; 2001 Dec; 194(12):1861-74. PubMed ID: 11748286
[TBL] [Abstract][Full Text] [Related]
18. FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma.
Wohlfart S; Sebinger D; Gruber P; Buch J; Polgar D; Krupitza G; Rosner M; Hengstschläger M; Raderer M; Chott A; Müllauer L
Am J Pathol; 2004 Mar; 164(3):1081-9. PubMed ID: 14982861
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies.
Nagel D; Vincendeau M; Eitelhuber AC; Krappmann D
Oncogene; 2014 Dec; 33(50):5655-65. PubMed ID: 24469030
[TBL] [Abstract][Full Text] [Related]
20. Immunodeficiency, autoimmunity, and increased risk of B cell malignancy in humans with
Rae W; Sowerby JM; Verhoeven D; Youssef M; Kotagiri P; Savinykh N; Coomber EL; Boneparth A; Chan A; Gong C; Jansen MH; du Long R; Santilli G; Simeoni I; Stephens J; Wu K; Zinicola M; Allen HL; Baxendale H; Kumararatne D; Gkrania-Klotsas E; Scheffler Mendoza SC; Yamazaki-Nakashimada MA; Ruiz LB; Rojas-Maruri CM; Lugo Reyes SO; Lyons PA; Williams AP; Hodson DJ; Bishop GA; Thrasher AJ; Thomas DC; Murphy MP; Vyse TJ; Milner JD; Kuijpers TW; Smith KGC
Sci Immunol; 2022 Aug; 7(74):eabn3800. PubMed ID: 35960817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
